Article Figures & Data
Tables
Demographic Characteristic Platelet Testing/PED Group PED Alone Group P Value No. (%) of patients 511 (73.2) 187 (26.8) Age, y Mean ± SD 58.1 ± 14.1 55.7 ± 13.2 .022 Median (minimum, maximum) 59 (9, 86) 57 (13, 81) No. (%) male 98 (19.2) 40 (21.4) .52 Follow-up duration, mo Mean ± SD 21.5 ± 8.0 23.5 ± 10.1 .20 Median (minimum, maximum) 20.8 (0.1, 48.0) 21.3 (0.2, 60.5) Total no. (%) of aneurysms 601 (74.8) 201 (25.2) No. (%) of patients with 1 aneurysm 438 (85.7) 176 (94.1) 2 aneurysms 61 (11.9) 9 (4.8) .008 ≥3 aneurysms 12 (2.4) 2 (1.1) Mean center volume ± SD, n 65 ± 45 63 ± 32 .06 Median center volume (minimum, maximum), n 47 (21, 149) 69 (19, 149) Mean practitioner volume ± SD, n 25 ± 15 21 ± 13 .004 Median practitioner volume (minimum, maximum), n 21 (1, 54) 21 (1, 54) Aneurysm size, mm Mean ± SD (n) 10.8 ± 7.7 (595) 12.0 ± 7.7 (200) .01 Median (minimum, maximum) 8.8 (1.0, 55.0) 10.5 (1.0, 40.0) Aneurysm location, % (n/N) Internal carotid artery 78.0 (469/601) 77.1 (155/201) Middle cerebral artery 4.7 (28/601) 3.0 (6/201) Posterior cerebral artery 1.7 (10/601) 1.0 (2/201) .11 Basilar artery 4.0 (24/601) 8.5 (17/201) Other 11.6 (70/601) 10.4 (21/201) Multiple PEDs used 38.0 (227/598) 27.9 (56/201) .01 Aneurysm shape, % (n/N) Saccular 76.9 (462/601) 77.1 (155/201) Fusiform 13.1 (79/601) 13.4 (27/201) .58 Dissecting 5.0 (30/601) 6.5 (13/201) Other 5.0 (30/601) 3.0 (6/201) Complication Platelet Testing/PED Group (N = 511) (% [n]) PED Alone Group (N = 187) (% [n]) P Value Primary outcome: neurologic morbidity and neurologic mortality 8.8 (45) 3.2 (6) .01 Secondary outcomes Spontaneous rupture 0.6 (3) 0.5 (1) 1 Intracranial hemorrhage 2.3 (12) 0.0 (0) .04 Ischemic stroke 5.5 (28) 2.1 (4) .07 Parent artery stenosis 0.2 (1) 0.5 (1) .46 Cranial neuropathy 0.4 (2) 0.0 (0) 1 Neurologic morbidity 8.2 (42) 2.1 (4) <.01 Neurologic mortality 3.5 (18) 1.1 (2) .12 All-cause mortality 4.1 (21) 1.1 (2) .05 - Table 3:
Multivariate logistic regression analysis: odds of complications according to platelet-testing status
Complication ORa 95% CI P Value Primary outcome: neurologic morbidity and neurologic mortality 2.37 0.95 to 5.93 .06 Secondary outcomes Spontaneous rupture 1.46 0.28 to 7.67 .65 Intracranial hemorrhage 6.56 0.50 to 85.80 .15 Ischemic stroke 2.03 0.67 to 6.20 .21 Parent artery stenosis 0.06 <0.001 to 24.51 .37 Cranial neuropathy 1.17 0.22 to 6.38 .85 Neurologic mortality 3.24 0.80 to 15.01 .13 Neurologic morbidity 3.25 1.10 to 9.61 .03 All-cause mortality 3.67 0.81 to 16.74 .09 ↵a Shown are the odds in the platelet testing/PED group versus those in the PED alone group. For each of the complications, the OR is for the platelet testing/PED versus the PED alone group. The analysis was adjusted for age, gender, aneurysm size, number of aneurysms treated, use of multiple PEDs, practitioner's previous experience, and center volume.
Jump to section
Related Articles
Cited By...
- Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update
- Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment
- Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update
- Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey
- Review of current intracranial aneurysm flow diversion technology and clinical use
- Considerations for Antiplatelet Management of Carotid Stenting in the Setting of Mechanical Thrombectomy: A Delphi Consensus Statement
- Antiplatelet Management for Stent-Assisted Coiling and Flow Diversion of Ruptured Intracranial Aneurysms: A DELPHI Consensus Statement
- Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU)
- Predictive value of platelet reactivity unit (PRU) value for thrombotic and hemorrhagic events during flow diversion procedures: a meta-analysis
- Antiplatelet therapy and the risk of ischemic and hemorrhagic complications associated with Pipeline embolization of cerebral aneurysms: a systematic review and pooled analysis
- Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysis
- Procedural complexity independent of P2Y12 reaction unit (PRU) values is associated with acute in situ thrombosis in Pipeline flow diversion of cerebral aneurysms
- Early angiographic signs of acute thrombus formation following cerebral aneurysm treatment with the Pipeline embolization device
- P2Y12 hyporesponse (PRU>200) is not associated with increased thromboembolic complications in anterior circulation Pipeline